Adverum Biotechnologies Inc (ADVM)
0.7577
+0.01
(+1.31%)
USD |
NASDAQ |
Mar 24, 16:00
0.76
0.00 (0.00%)
After-Hours: 20:00
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 74.79M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -44.60% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 0.3590 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 97.89% |
News
Headline
Wire
Time (ET)
MT Newswires
03/07 09:55
Yahoo
03/02 10:23
MT Newswires
11/11 08:06
MT Newswires
11/11 07:00
Globe Newswire
09/30 16:45
Globe Newswire
09/23 16:05
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 03/29/2023* | -- | Results | Q4 2022 | -- | -0.39 | -- | |
| 11/10/2022 | -- | Results | Q3 2022 | -0.40 | -0.37 | -7.14% | |
| 08/11/2022 | -- | Results | Q2 2022 | -0.44 | -0.29 | -51.72% | |
| 05/12/2022 | -- | Results | Q1 2022 | -0.38 | -0.30 | -25.28% | |
| 03/29/2022 | -- | Results | Q4 2021 | -0.35 | -0.31 | -12.90% | |
| 11/04/2021 | -- | Results | Q3 2021 | -0.39 | -0.37 | -6.36% | |
| 08/05/2021 | -- | Results | Q2 2021 | -0.45 | -0.38 | -18.37% | |
| 05/06/2021 | -- | Results | Q1 2021 | -0.29 | -0.38 | 23.18% |
*Estimated Date/Time
Earnings
Profile
Edit
| Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. |
| URL | https://www.adverum.com |
| Investor Relations URL | https://investors.adverum.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Mar. 29, 2023 (est.) |
| Last Earnings Release | Nov. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 23, 2023.
Fundamentals
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 157.61M |
| Net Income (TTM) | -156.21M |
| Total Assets (Quarterly) | 332.36M |
| Total Liabilities (Quarterly) | 124.02M |
| Shareholders Equity (Quarterly) | 208.34M |
| Cash from Operations (TTM) | -115.43M |
| Cash from Investing (TTM) | 163.37M |
| Cash from Financing (TTM) | 0.74M |
Ratings
Profile
Edit
| Adverum Biotechnologies Inc is a U.S.-based clinical-stage gene therapy company. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. The company primarily generates revenue through license, research and collaboration arrangements with its strategic partners. Its lead product candidate is ADVM-022 which is a single, in-office intravitreal (IVT) injection gene therapy designed to deliver long-term durable levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with frequent anti-vascular endothelial growth factor (VEGF) injections. |
| URL | https://www.adverum.com |
| Investor Relations URL | https://investors.adverum.com |
| HQ State/Province | California |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | Mar. 29, 2023 (est.) |
| Last Earnings Release | Nov. 10, 2022 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| ADVM Tweets |